Jonathan Strober, MD, discusses advancements in pediatric myasthenia gravis, emphasizing the need for better treatment standards and effective patient care strategies.
Immunovant shifts primary focus to IMVT-1402, a next-generation anti-FcRn, targeting Graves' Disease with potential ...
Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new ...
Discover Vor BiopharmaVor Biopharma Inc.'s potential with telitacicept amid funding challenges and market risks. Click for ...
Zacks Investment Research on MSN
JNJ vs. PFE: Which blue-chip drug stock is the better investment now?
Johnson & Johnson JNJ and Pfizer PFE are both healthcare leaders with large drug portfolios and diversified revenue streams, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback